Isopoint IV Injection is a clinically established pharmaceutical preparation containing IRON(III)ISOMALTOSIDE as its primary active ingredient. It falls under the Hematology therapeutic class and is widely used for the management of associated medical conditions. The medicine exerts its action through a well-defined pharmacological mechanism. Manufactured by Sun Pharmaceutical, Isopoint IV Injection is available in Injection form. This medicine is classified under the Blood Disorder general category and the Hematology speciality domain, reflecting its targeted use in managing conditions within this therapeutic area.

• Primary Indication: Management and treatment of conditions in the Hematology therapeutic domain as diagnosed and confirmed by a qualified specialist. • Combination Therapy: May be used as part of a multi-drug regimen. • Monotherapy: Can be prescribed as a standalone agent where appropriate. • Maintenance Therapy: Used for disease control following initial stabilization. • Prophylaxis: Prescribed preventively in high-risk patients where applicable.

Isopoint IV Injection containing IRON(III)ISOMALTOSIDE exerts its therapeutic effects through a well-defined pharmacological mechanism relevant to blood disorder conditions, interacting with specific molecular targets to produce the desired clinical effect within the Hematology speciality domain.

• Always inform your doctor about every medicine you are currently taking before starting Isopoint IV Injection — prescription drugs, OTC medications, vitamins, and herbal products. • Concurrent use with other blood disorder-related medicines should be supervised by a specialist. • Carry a complete updated medicine list whenever visiting any healthcare provider.

Isopoint IV Injection is a prescription-only medicine and must not be purchased or used without a valid prescription from a licensed medical practitioner. Storage: Store below 25°C. Protect from moisture. Manufactured by Sun Pharmaceutical and complies with applicable drug regulatory standards. Report any adverse effects to your doctor and to CDSCO (India) through the ADR reporting system.